AAREYDRUGS94.99

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersNECLIFENATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹270 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation1.71.92.9
+ Finance Costs0.04.05.0
+ Other Non-cash Items0.00.125.3
+ Other Reconciling Items0.00.00.0
Changes in Working Capital
+ Inventories-5.9-10.83.9
+ Trade Receivables — Current0.054.93.8
+ Trade Receivables — Non-current5.30.00.0
+ Other Financial Assets — Current-0.939.5-13.9
+ Other Current Assets-3.2-14.4-0.2
+ Trade Payables — Current1.6-74.8-21.0
+ Other Financial Liabilities — Current3.25.1-0.0
+ Other Current Liabilities0.00.01.1
+ Provisions — Current-0.10.0-0.6
Cash from Operating Activities
Profit Before Tax (per I/S)5.36.15.44.2
+ Total Adjustments (incl. Working Capital)1.95.56.3
Cash from Operations (pre-tax)7.211.611.7
+ Income Taxes Paid-0.71.91.6
Cash from Operating Activities7.99.710.1
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)0.00.012.4
+ Disp of Intangible Assets-1.00.00.0
+ Disp of Investment Property0.0-5.20.0
+ Acq of Other Long-term Assets-0.70.00.0
+ Disp of Other Long-term Assets-1.10.00.0
+ Loans & Advances Made-0.00.00.0
+ Loans & Advances Repaid-6.50.00.0
+ Interest Received — Investing0.0-0.70.0
+ Income Taxes (Paid) / Refund — Investing-0.50.00.0
+ Other Inflows / (Outflows) — Investing0.10.00.0
Cash from Investing Activities-7.3-5.9-12.4
Cash from Financing Activities
+ Proceeds from Issue of Shares2.71.70.0
+ Proceeds from Other Equity Instruments0.60.00.0
+ Proceeds from Borrowings-5.20.00.0
+ Repayment of Borrowings0.01.50.0
+ Interest Paid0.04.00.0
+ Income Taxes (Paid) / Refund — Financing1.30.00.0
+ Other Inflows / (Outflows) — Financing7.4-0.02.2
Cash from Financing Activities4.1-3.82.2
Net Changes in Cash (pre-FX)4.7-0.1-0.1
Net Changes in Cash4.7-0.1-0.1
Closing Cash5.4
Reference Items
EBITDA4.52.37.26.8
EBITDA Margin %1.130.481.521.64
Free Cash Flow (CFO − Capex)7.99.7-2.3-2.3
Free Cash Flow to Equity9.112.8
Free Cash Flow per Basic Share2.773.39-0.80-0.80
Cash Flow to Net Income1.682.402.56
Cash Paid for Taxes-0.71.91.6
Cash Paid for Interest0.04.00.0
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.